06 October 2025
Top hires for Q3-2025
In the third quarter of 2025 Coulter Partners drove global executive search for a wide range of life sciences, health, and technology organizations.
We successfully placed executives for venture capital & private equity-backed firms, alongside large-cap, mid-cap, and public companies, filling critical roles across diverse disciplines worldwide.
CEO/ C-suite/ Board
|
Function |
Focus area |
Ownership |
Location |
|
CEO |
Diagnostic & laboratory services |
PE-backed |
France |
|
CEO |
Small-molecule therapies |
VC-backed |
Italy |
|
CEO |
Bio-storage solutions |
PE-backed |
UK |
|
CEO |
Cell & gene therapies |
VC-backed |
Denmark |
|
Chief Financial Officer |
Medical devices |
VC-backed |
France |
|
Chief Financial Officer |
Cell therapies |
Publicly listed |
US |
|
Chief Scientific Officer |
tRNA platform company |
VC-backed |
US |
|
Chief Scientific Officer |
Protein degrader therapeutics |
VC-backed |
Italy |
|
Chief Business Officer |
Regenerative macrophage therapies |
VC-backed |
US |
|
Chief Business Officer |
Pediatric medicines |
VC-backed |
UK |
|
Chief Operating Officer |
Industry catapult |
Not-for-Profit |
UK |
|
Chair |
Contract Research Organization |
Publicly listed |
UK |
|
Board Director |
Regulatory T cells (Tregs) |
VC-backed |
US |
|
Board Director |
Small-molecule inhibitors |
VC-backed |
US |
|
Board Director |
APIs |
Independently-owned |
Spain |
Commercial/Functional/Strategic
|
Function |
Focus area |
Ownership |
Location |
|
VP, Commercial Strategy International |
Specialty pharma |
Publicly listed |
US / UK |
|
Country CEO |
Dental services |
PE-backed |
Denmark |
|
Country CEO |
Engineering consultancy services |
PE-backed |
Norway |
|
Global Head of Communications |
Generics |
Publicly listed |
UK |
|
General Manager |
APIs / Pharma |
Family-owned |
Italy |
|
Country General Manager |
Biopharma |
Publicly listed |
Australia |
|
Country General Manager |
Medical instrumentation |
Family-owned |
UK |
|
Market Access Director |
Specialty pharma |
Independently-owned |
France |
|
Region Finance Director |
Medical devices |
PE-backed |
Sweden |
|
Sales Managers |
Pharma capex solutions |
PE-backed |
US |
R&D/Medical/Technical
|
Function |
Focus area |
Ownership |
Location |
|
SVP, Quality |
Pharmaceutical services |
PE-backed |
Ireland |
|
VP, International Regulatory Strategy |
Specialty biopharma |
Publicly listed |
UK |
|
VP, CMC |
MASH therapeutics |
Publicly listed |
US |
|
VP, Global Medical Affairs, Obesity |
Top 10 global pharma |
Publicly listed |
Denmark / US |
|
AVP, Technical Operations |
Organ manufacturing |
Publicly listed |
US |
|
Global Head Biometric Sciences |
Specialty pharma |
Family-owned |
Switzerland |
|
Global Head Toxicology Services |
Laboratory services |
PE-backed |
Germany |
|
Market Value & Evidence Lead |
Specialty pharma |
Family-owned |
Italy |
|
Head of Pharmacovigilance |
Drug discovery |
Publicly listed |
Switzerland |
|
Global R&D Director |
Wound care products |
PE-backed |
Germany |
|
Executive Medical Director, Obesity |
Top 10 global pharma |
Publicly listed |
US |
|
Industrial Director |
Specialty ingredients |
PE-backed |
France |
Related
-
Events
AusBiotech 2025
21 October 2025 – 24 October 2025
-
Company News
LSX World Congress conference with Justine McIlroy, Client Partner
12 May 2023
-
Thought Leadership
Five Shifts to Digital Personalized Healthcare
10 May 2023
-
Company News
Digital Health UK CEO and Commercial Leaders Breakfast
28 March 2023
